Summary
The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.
Competing Interest Statement
In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents.
Clinical Trial
NCT04380701
Funding Statement
BioNTech is the Sponsor of the clinical trial study that the human samples were obtained from, N.P. was supported by the NIAID -1R01AI146101, U.S, and C.B. work for BioNTech, M.L. was supported by NIAID - R01AI123738). D.W. was supported by grants from the NIAID - AI142596 and AI124429, IPCAVD - U19AI142596, and BioNTech. B.H. was funded by a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and NIH grant IPCAVD-U19AI142596, P.A. was funded by NIAID R01 - AI145687 and a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), D.M. was funded by NIH - HHSN272201800004C, the Gates Foundation - OPP1146996 and a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). B.K. was funded by the Los Alamos National Laboratory directed research (LDRD) project 20200706ER
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was carried out in Germany in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an independent ethics committee (Ethik-Kommission of the Landesarztekammer Baden-Wurttemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich Institute, Langen, Germany). All participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
I will share all primary data generated as part of this grant. It will be deposited at the National Addiction & HIV Data Archive Program (NAHDAP), which is an NIH-funded repository. Collected samples will be stored at the University of Pennsylvania and available after review of the request by the PI.
